The role of complement in dendritic cell (DC) control of T-cell subsets.
This section of the Journal of Drugs in Dermatology (JDD) is dedicated to Dendreon's Provenge (Sipuleucel-T), the first therapeutic DC vaccine proven effective and approved by the United States (U.S.) Food and Drug Administration (FDA) for advanced cancer. This editorial will discuss three articles in this issue, their relationship to Provenge and the recent TH17-Treg subsets that are regulated by CD46.
William R
WR
Levis
Frank
F
Martiniuk
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003165:Complement System Proteins / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014020:Tissue Extracts / Q000276:immunology
D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T; D003165:Complement System Proteins